Chemotherapy-induced Peripheral Neuropathy Clinical Trial
Official title:
Effect of Massage Therapy on Peripheral Neuropathy and Life Quality of Colorectal Cancer wıth Patient Receiving Chemotherapy
NCT number | NCT05433246 |
Other study ID # | 2011/211 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 1, 2012 |
Est. completion date | May 1, 2013 |
Verified date | July 2023 |
Source | Akdeniz University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this randomized controlled experimental study was to determine the effect of massage applied to colorectal cancer patients receiving chemotherapy on peripheral neuropathy and quality of life.
Status | Completed |
Enrollment | 52 |
Est. completion date | May 1, 2013 |
Est. primary completion date | May 1, 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - over 18 years old - have a diagnosis of colorectal cancer - receiving FOLFOX-4 chemotherapy protocol - to receive a maximum of 4 cycles of FOLFOX-4 chemotherapy - platelet values over -100.000/mm3 - no obstacle to massage application Exclusion Criteria: - previously been diagnosed with polyneuropathy, - has been diagnosed with diabetes, - is addicted to alcohol, - has been amputated at the extremities, - has a skin infection and skin integrity disorder, - has megaloblastic anemia, uses anticoagulants, - takes drugs that hide or affect neuropathy findings - has had massage therapy within the last month. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fatma Arikan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peripheral Neuropathy Evaluation Form | It was developed by the researcher by reviewing the literature in order to determine the symptoms of peripheral neuropathy in the upper and lower extremities of the patients (0=no symptoms, 4=very severe) | 16 week | |
Primary | Self-Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (S-LANSS) | This scale measures neuropathic pain.The first five items of the scale show pain symptoms, while the last two items show allodynia and pinprick test self-report. A score of twelve points or more is considered as neuropathic pain (neuropathic pain yes:12 and higher). | 16 weeks | |
Primary | MD Anderson Symptom Inventory | The scale includes symptoms (13 items), and measures how much the symptoms have interfered with six daily activities (general activity, mood, work, relations with others, walking, and enjoyment of life.) A high score indicates an increase in the severity of the symptom and negative impact on life. The rates the severity of symptoms with a score of 0-10, 0 "none" and 10 "as bad as you can imagine" over the past 24 hours.Interference is rated on a 0-10 numerical rating scale, 0 being "did not interfere" and 10 being "interfered completely." A score range of 5-6 is considered "moderate" and a range of 7-10 is considered "severe". | 16 weeks | |
Primary | European Organisation for Research and Treatment of Cancer-Quality of Life Scale | It measures the quality of life of individuals diagnosed with cancer. This scale consists of three parts: general health, functional health and symptoms, and a total of 30 questions ((minimum score: 0 maximum score: 100).A high score indicates a high quality of life. Low scores on functional health (physical, role, emotional, cognitive, and social functions) and general health scales indicate poor quality of life. Low scores on the symptom subscale indicate higher quality of life. | 16 weeks | |
Primary | American National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0 | It was used to grade Peripheral Neuropathy-sensory (minimum score: 0; maximum score: 4). Grade 0: Normal, no symptoms, Grade 4: permanent loss of sensation and impaired function. High grades indicate the height of the symptom severity. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
Completed |
NCT03272919 -
Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
Not yet recruiting |
NCT06430814 -
Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
|
||
Not yet recruiting |
NCT05840562 -
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT02553863 -
The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04786977 -
Physiologic Measure of VIPN
|
||
Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
Completed |
NCT03687970 -
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
|
N/A | |
Terminated |
NCT04770402 -
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
|
N/A | |
Completed |
NCT03254394 -
Lidocaine for Oxaliplatin-induced Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT04367480 -
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04237194 -
A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
|
||
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Terminated |
NCT03782402 -
Cannabinoids for Taxane Induced Peripheral Neuropathy
|
Phase 2 | |
Not yet recruiting |
NCT06389721 -
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
|
||
Recruiting |
NCT05121558 -
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
|
Phase 3 | |
Withdrawn |
NCT04492436 -
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
|
Phase 2 | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT04262778 -
Diagnostic of Chemotherapy Induced Neuropathy in Children
|
||
Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A |